Non-technical Abstract 
Non-Technical Abstract 
Many types of cancer are resistant to available medical treatments including drugs, 
chemotherapy, surgery and radiation, alone or in combinations. The intent of the 
proposed treatment is to evaluate the clinical response to the expansion of lymphocytes 
which respond specifically to tumor antigens. In this study, an experimental procedure 
will be conducted which will attempt to fight cancer by injecting genetic material, DNA, 
directly into solid tumors. The DNA is mixed with lipid to form a complex, and this 
complex will be injected into the tumor. DNA will be taken into cells causing them to 
produce and secrete a protein that stimulates the immune system. This protein, called 
Interleukin-2 (IL-2), causes cells which secrete it to recruit immune cells to the tumor 
site, which may lead to tumor reduction or eradication. 
The IL-2 protein has been approved for cancer therapy in renal cell carcinoma, and is 
undergoing advanced clinical evaluation for treatment of melanoma. The proposed 
study targets production of IL-2 directly in the tumor to attract and stimulate th'e 
immune response required for tumor regression. In this study, we will attempt to learn 
the range of safe and effective doses of the DNA /lipid complex. Increasing amounts of 
this complex will be administered in patients with a variety of solid tumors or 
lymphomas. If no side effects are observed, the procedure will be repeated up to six 
times. This treatment may provide a potent therapeutic effect in cancer, based on a 
well-characterized protein in a potentially toxicity-free delivery mechanism. 
Recombinant DNA Research, Volume 20 
[598] 
L 
